These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22223502)

  • 21. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution.
    Lennerz JK; Rühle V; Ceppa EP; Neuhuber WL; Bunnett NW; Grady EF; Messlinger K
    J Comp Neurol; 2008 Mar; 507(3):1277-99. PubMed ID: 18186028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
    Bigal ME; Walter S; Rapoport AM
    Headache; 2013 Sep; 53(8):1230-44. PubMed ID: 23848260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blocking CGRP in migraine patients - a review of pros and cons.
    Deen M; Correnti E; Kamm K; Kelderman T; Papetti L; Rubio-Beltrán E; Vigneri S; Edvinsson L; Maassen Van Den Brink A;
    J Headache Pain; 2017 Sep; 18(1):96. PubMed ID: 28948500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A potent and selective calcitonin gene-related peptide (CGRP) receptor antagonist, MK-8825, inhibits responses to nociceptive trigeminal activation: Role of CGRP in orofacial pain.
    Romero-Reyes M; Pardi V; Akerman S
    Exp Neurol; 2015 Sep; 271():95-103. PubMed ID: 25981890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the pharmacotherapy of migraine. How knowledge of pathophysiology is guiding drug development.
    Goadsby PJ
    Drugs R D; 1999 Dec; 2(6):361-74. PubMed ID: 10763443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting CGRP: A New Era for Migraine Treatment.
    Wrobel Goldberg S; Silberstein SD
    CNS Drugs; 2015 Jun; 29(6):443-52. PubMed ID: 26138383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Migraine models.
    Benemei S; De Cesaris F; Nicoletti P; Materazzi S; Nassini R; Geppetti P
    Methods Mol Biol; 2010; 617():105-14. PubMed ID: 20336417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.
    Pellesi L; Guerzoni S; Pini LA
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):534-547. PubMed ID: 28409893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.
    Yuan H; Lauritsen CG; Kaiser EA; Silberstein SD
    BioDrugs; 2017 Dec; 31(6):487-501. PubMed ID: 29116598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modelling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist.
    Trocóniz IF; Wolters JM; Tillmann C; Schaefer HG; Roth W
    Clin Pharmacokinet; 2006; 45(7):715-28. PubMed ID: 16802852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine.
    Rudolf K; Eberlein W; Engel W; Pieper H; Entzeroth M; Hallermayer G; Doods H
    J Med Chem; 2005 Sep; 48(19):5921-31. PubMed ID: 16161996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CGRP and its receptors provide new insights into migraine pathophysiology.
    Ho TW; Edvinsson L; Goadsby PJ
    Nat Rev Neurol; 2010 Oct; 6(10):573-82. PubMed ID: 20820195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging Treatments in Episodic Migraine.
    Grimsrud KW; Halker Singh RB
    Curr Pain Headache Rep; 2018 Jul; 22(9):61. PubMed ID: 30014208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier.
    Eftekhari S; Salvatore CA; Johansson S; Chen TB; Zeng Z; Edvinsson L
    Brain Res; 2015 Mar; 1600():93-109. PubMed ID: 25463029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Migraine.
    Benemei S; Nicoletti P; Capone JG; De Cesaris F; Geppetti P
    Handb Exp Pharmacol; 2009; (194):75-89. PubMed ID: 19655105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging drugs for migraine treatment.
    Giamberardino MA; Martelletti P
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):137-47. PubMed ID: 25547922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Recent advances in the elucidation of migraine pathophysiology].
    Nagata E
    Rinsho Shinkeigaku; 2020 Jan; 60(1):20-26. PubMed ID: 31852874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine.
    Levy D; Burstein R; Strassman AM
    Ann Neurol; 2005 Nov; 58(5):698-705. PubMed ID: 16240341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cortical spreading depression and pain: a missing link in the pathophysiology of migraine?].
    Kowa H; Takigawa H; Nakashima K
    Rinsho Shinkeigaku; 2014; 54(12):1006-8. PubMed ID: 25672694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.
    Ong JJY; Wei DY; Goadsby PJ
    Drugs; 2018 Mar; 78(4):411-437. PubMed ID: 29396834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.